Larimar Therapeutics
LRMR
40 hedge funds and large institutions have $28.2M invested in Larimar Therapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 5 closing their positions.
4.88% less ownership
Funds ownership: 86.15% → 81.27% (-4.9%)
11% less funds holding
Funds holding: 45 → 40 (-5)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less capital invested
Capital invested by funds: $61.8M → $28.2M (-$33.6M)
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$174K |
| 2 |
Renaissance Technologies
New York
|
+$8.27K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.3K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$230 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$139 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$875K |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$740K |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$405K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$343K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$224K |
LRMR Hedge Fund Activity: Q2 2022 in Review
40 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2022, worth a combined $28.2M — down 54% from $61.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LRMR and 1 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 4 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $174K. The largest seller was Janus Henderson Group, cutting an estimated $875K.
- 40 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2022, down from 45 in Q1 2022.
- Funds reported $28.2M of Larimar Therapeutics stock for Q2 2022, down 54% quarter-over-quarter.
- 1 fund opened new Larimar Therapeutics positions in Q2 2022 and 5 closed out, a net change of -4 holders.
- The largest Larimar Therapeutics buyer in Q2 2022 was Bridgeway Capital Management, an estimated $174K added.
- The largest Larimar Therapeutics seller in Q2 2022 was Janus Henderson Group, an estimated $875K sold.
Based on aggregated 13F filings for Q2 2022.